BioGaia is a Swedish biotechnology company focused on the research, development, and commercialization of probiotic bacteria for human health. Its core expertise spans strain discovery, clinical evaluation, and formulation of lactic acid bacteria—including Limosilactobacillus reuteri—into stable consumer-ready formats such as drops, chewable tablets, and lozenges. BioGaia’s products target areas including gastrointestinal, pediatric, immune, and oral health and are distributed through healthcare and retail channels in numerous international markets. The company combines in-house R&D with academic collaborations and outsourced GMP fermentation and manufacturing, supported by an extensive portfolio of clinical studies and quality systems aligned with regulatory standards for dietary supplements and related categories.
Through subsidiaries such as MetaboGen AB, BioGaia also advances next-generation microbiome strains and precision fermentation technologies. Headquartered in Sweden and listed on Nasdaq Stockholm, the company operates at the interface of the chemical and life sciences industries, with capabilities in microbial fermentation process development, freeze-drying, encapsulation, and stability optimization for active cultures, alongside safety and regulatory assessments.
